Akzo IPO bid on a roll

Gibson, Jane
March 2007
ICIS Chemical Business;3/12/2007, Vol. 2 Issue 57, p13
Trade Publication
The article reports on the confirmation by Akzo Nobel that it will proceed with the timing of its planned partial initial public offering (IPO) of its Organon and Intervet business scheduled for March 2007 in the light of global stock market declines. Akzo Nobel is facing demands that a proportion of the proceeds from the IPO be distributed as a bonus to Akzo Nobel staff in the Netherlands.


Related Articles

  • Organon attracts three buyers. Ovrebekk, Hilde; Gibson, Jane // ICIS Chemical Business Americas;1/22/2007, Vol. 271 Issue 3, p12 

    The article reports on the potential takeover bidders for Organon, the pharmaceuticals division of Akzo Nobel. The interested private equity firms include Carlyle Group and Cinven, the Blackstone Group, and a group including Kohlberg Kravis Roberts & Co. Akzo Nobel has maintained that an initial...

  • Agreements.  // Medical Device Daily;10/3/2007, Vol. 11 Issue 189, p4 

    The article reports that Organon, the healthcare business unit of Akzo Nobel, has extended its GeneGo software and database licenses. GeneGo is a provider of systems biology tools. Aside from the MetaCore license extension, Organon has also added MetaLink to upload its own interaction data and...

  • Akzo merges its pharma units. Tyler, Alan // European Chemical News;9/13/2004, Vol. 81 Issue 2115, p28 

    Reports on the plan of Akzo Nobel to integrate its Diosynth and Organon pharmaceutical businesses and to build a production facility in Oss, the Netherlands. Other plans of Akzo; Background on Diosynth and Organon.

  • Akzo Restructures "to Fix" Pharmaceuticals. Scott, Alex // Chemical Week;9/8/2004, Vol. 166 Issue 29, p12 

    Reports on the plan of Akzo Nobel to restructure its pharmaceutical intermediates business Diosynth as of September 2004. Integration of Diosynth with its human health care business Organon; Number of affected jobs due to the restructuring of Diosynth; Amount of investment needed to build...

  • AkzoNobel Unveils Link between Color Use and Economic Trends.  // China Chemical Reporter;8/6/2009, Vol. 20 Issue 22, p8 

    The article reports on the research of color trends, conducted by AkzoNobel Decorative Paints. It was found that people's choice and use of color is influenced strongly by the state of the economy. As the economy has ebbed and flowed, trends in interior design have been fluctuating. Neutral...

  • Akzo Nobel and Organon break up. Robinson, Simon // ICIS Chemical Business;8/28/2006, Vol. 1 Issue 32, p11 

    The article reports on the planned separation of Akzo Nobel and Organon into two independent businesses. Akzo Nobel intends to sell its 20-30% stake of its Organon Biosciences through an initial public offering in Amsterdam, Netherlands. Akzo chairman Hans Wijers believes that the presentation...

  • Akzo Nobel to divide via pharma spin-off. Robinson, Simon // ICIS Chemical Business;2/13/2006, Vol. 1 Issue 6, p10 

    The article reports on the decision of Akzo Nobel to split into two independent companies, namely Coatings/Chemicals and Pharmaceuticals, by spinning off its pharmaceuticals business. A minority stake in the pharmaceuticals business will be sold through an initial public offering in 2006. Akzo...

  • Akzo Nobel quiet on Organon sale. Ovrebekk, Hilde; Gibson, Jane // ICIS Chemical Business;1/8/2007, Vol. 2 Issue 48, p8 

    This article states that Akzo Nobel is in talks with private equity companies about the sale of its drugs unit Organon, Dutch newspaper Het Financieele Dagblad said last week, quoting anonymous sources. Akzo Nobel, however, denied plans to sell instead of going ahead with its planned initial...

  • Akzo plays down Organon sale. Ovrebekk, Hilde; Davis, Nigel; Chang, Joseph // ICIS Chemical Business Americas;1/8/2007, Vol. 271 Issue 1, p6 

    The article reports that Akzo Nobel denied its plan to sell its Organon drugs business to private equity instead of going ahead with its initial public offering (IPO) plan. The sale of Organon human health care and the Intervet animal health businesses to private investors continue to eye a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics